Allarity Therapeutics (ALLR) Competitors $1.01 -0.03 (-2.88%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.01 +0.00 (+0.50%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLR vs. VRCA, HOWL, IFRX, ICCC, ATHE, DTIL, KLTO, ADVM, ANVS, and ALGSShould you be buying Allarity Therapeutics stock or one of its competitors? The main competitors of Allarity Therapeutics include Verrica Pharmaceuticals (VRCA), Werewolf Therapeutics (HOWL), InflaRx (IFRX), ImmuCell (ICCC), Alterity Therapeutics (ATHE), Precision BioSciences (DTIL), Klotho Neurosciences (KLTO), Adverum Biotechnologies (ADVM), Annovis Bio (ANVS), and Aligos Therapeutics (ALGS). These companies are all part of the "pharmaceutical products" industry. Allarity Therapeutics vs. Its Competitors Verrica Pharmaceuticals Werewolf Therapeutics InflaRx ImmuCell Alterity Therapeutics Precision BioSciences Klotho Neurosciences Adverum Biotechnologies Annovis Bio Aligos Therapeutics Allarity Therapeutics (NASDAQ:ALLR) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk. Do analysts recommend ALLR or VRCA? Allarity Therapeutics presently has a consensus target price of $9.00, indicating a potential upside of 791.09%. Verrica Pharmaceuticals has a consensus target price of $80.00, indicating a potential upside of 1,318.44%. Given Verrica Pharmaceuticals' higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Allarity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media favor ALLR or VRCA? In the previous week, Allarity Therapeutics had 4 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 7 mentions for Allarity Therapeutics and 3 mentions for Verrica Pharmaceuticals. Allarity Therapeutics' average media sentiment score of 0.85 beat Verrica Pharmaceuticals' score of 0.41 indicating that Allarity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ALLR or VRCA more profitable? Verrica Pharmaceuticals' return on equity of 0.00% beat Allarity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allarity TherapeuticsN/A -147.94% -90.33% Verrica Pharmaceuticals N/A N/A -145.63% Which has preferable valuation and earnings, ALLR or VRCA? Allarity Therapeutics has higher earnings, but lower revenue than Verrica Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllarity TherapeuticsN/AN/A-$24.51MN/AN/AVerrica Pharmaceuticals$7.57M6.89-$76.58M-$12.00-0.47 Do insiders & institutionals believe in ALLR or VRCA? 11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 0.1% of Allarity Therapeutics shares are held by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, ALLR or VRCA? Allarity Therapeutics has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. SummaryVerrica Pharmaceuticals beats Allarity Therapeutics on 6 of the 11 factors compared between the two stocks. Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLR vs. The Competition Export to ExcelMetricAllarity TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.68M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E RatioN/A17.6228.7823.81Price / SalesN/A179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book0.628.508.275.54Net Income-$24.51M-$55.06M$3.25B$259.28M7 Day Performance-0.98%-3.99%-3.70%-4.64%1 Month Performance1.00%9.58%4.34%4.41%1 Year Performance-79.14%6.70%25.90%17.95% Allarity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLRAllarity Therapeutics2.7332 of 5 stars$1.01-2.9%$9.00+791.1%-80.9%$15.68MN/A0.0010Upcoming EarningsAnalyst DowngradeAnalyst RevisionGap DownVRCAVerrica Pharmaceuticals3.9027 of 5 stars$6.79+2.7%$80.00+1,078.2%-91.1%$61.14M$7.57M-0.5740News CoverageShort Interest ↑HOWLWerewolf Therapeutics3.8921 of 5 stars$1.35-0.7%$8.33+517.3%-49.6%$61.03M$1.88M-0.8140News CoveragePositive NewsIFRXInflaRx3.1878 of 5 stars$0.88-2.4%$6.60+652.7%-43.4%$60.33M$180K-1.0760News CoverageUpcoming EarningsICCCImmuCell0.0834 of 5 stars$6.70+1.3%N/A+49.3%$59.74M$26.49M-95.6970Gap UpATHEAlterity Therapeutics1.7589 of 5 stars$5.58-14.8%$12.00+115.1%+234.0%$58.08MN/A0.0010Upcoming EarningsGap DownHigh Trading VolumeDTILPrecision BioSciences4.0888 of 5 stars$5.10-1.0%$47.00+821.6%-51.7%$57.10M$51.14M-2.54200KLTOKlotho NeurosciencesN/A$1.13-8.1%N/AN/A$56.65MN/A-3.14N/AGap DownADVMAdverum Biotechnologies4.2764 of 5 stars$2.65-1.9%$23.80+798.1%-69.4%$56.40M$1M-0.41190Positive NewsANVSAnnovis Bio2.008 of 5 stars$2.94+1.7%$18.00+512.2%-72.5%$56.31MN/A-1.363ALGSAligos Therapeutics4.2669 of 5 stars$8.76-4.1%$70.00+699.1%-43.7%$55.82M$3.27M-0.5090News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies Verrica Pharmaceuticals Alternatives Werewolf Therapeutics Alternatives InflaRx Alternatives ImmuCell Alternatives Alterity Therapeutics Alternatives Precision BioSciences Alternatives Klotho Neurosciences Alternatives Adverum Biotechnologies Alternatives Annovis Bio Alternatives Aligos Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLR Stock Alerts